US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BlossomHill Therapeutics

19.17

+0.18000.95%

Volume:44.62K

Turnover:859.54K

Market Cap:587.44M

PE:-7.84

High:19.91

Open:19.10

Low:18.84

Close:18.99

52wk High:20.61

52wk Low:15.25

Shares:30.64M

Float Shares:9.38M

Volume Ratio:0.67

T/O Rate:0.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4440

EPS(LYR):-24.8342

ROE:--

ROA:--

PB:-3.86

PE(LYR):-0.77

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target

MT Newswires Live

BlossomHill Therapeutics to Present Updated Phase 1/2 Solara Trial Data on BH-30643 in EGFR-Mutant NSCLC at WCLC 2026

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BlossomHill Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BLSM"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"BlossomHill Therapeutics","latestPrice":19.17,"timestamp":1788369480885,"preClose":18.99,"halted":0,"volume":44621,"delay":0,"changeRate":0.009478672985782163,"floatShares":9375000,"shares":30643700,"eps":-2.444,"marketStatus":"Trading","change":0.18,"latestTime":"09-02 13:18:55 EDT","open":19.1,"high":19.91,"low":18.84,"amount":859539.2313100001,"amplitude":0.056345,"askPrice":19.32,"askSize":308,"bidPrice":19.02,"bidSize":201,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":18.99,"preHourTrading":{"tag":"盘前","latestPrice":18.99,"preClose":18.99,"latestTime":"08:28 EDT","volume":665,"amount":12584.501895,"timestamp":1788352132198,"change":0,"changeRate":0,"amplitude":0.055819},"postHourTrading":{"tag":"盘后","latestPrice":18.99,"preClose":18.99,"latestTime":"19:30 EDT","volume":23,"amount":439.9,"timestamp":1788305400393,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.673159},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":0.673159,"shares":30643700,"dividePrice":0,"high":19.91,"amplitude":0.056345,"preClose":18.99,"low":18.84,"week52Low":15.25,"pbRate":"-3.86","week52High":20.6104,"institutionHeld":0,"latestPrice":19.17,"committee":-0.210216,"eps":-2.444,"divideRate":0,"volume":44621,"delay":0,"ttmEps":-2.444,"open":19.1,"prevYearClose":16,"prevWeekClose":19.56,"prevMonthClose":18.3,"prevQuarterClose":16,"fiveDayClose":18.46,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-09-01","current":-7.843699,"percent":0.222222,"low":-8.535478,"twenty":-7.909543,"median":-7.000816,"eighty":-6.897356,"high":-2.788792,"avg":-7.059563,"sd":1.141865,"marketCap":560778978},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828},{"date":"2026-08-28","current":-8.535478,"twenty":-7.10945,"median":-6.974951,"eighty":-6.897356,"marketCap":606744468},{"date":"2026-09-01","current":-7.888851,"twenty":-7.909543,"median":-7.000816,"eighty":-6.897356,"marketCap":560778978}],"updateTime":1788369535343},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BLSM\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664285564","title":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285564","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285564?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:24","pubTimestamp":1788261848,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664537848","title":"BlossomHill Therapeutics to Present Updated Phase 1/2 Solara Trial Data on BH-30643 in EGFR-Mutant NSCLC at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664537848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664537848?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:03","pubTimestamp":1788260634,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026BlossomHill flagged updated Phase 1/2 SOLARA data for BH-30643 in EGFR-mutant NSCLC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL406lNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BLSM","IE00BQXX3C00.GBP","BK4112","IE00BQXX3D17.EUR","BK4585","IE00BQXX3F31.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4007","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","NDAQ","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853002","title":"BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853002?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353953/0/en/blossomhill-therapeutics-to-present-updated-data-from-ongoing-phase-1-2-solara-trial-of-its-macrocyclic-omni-egfr-inhibitor-bh-30643-in-egfr-mutant-nsclc-at-the-2026-world-conferen.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853384","title":"BlossomHill Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853384?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:42","pubTimestamp":1788259320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLSM/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BLSM\",params:#limit:6,delay:false,,,undefined,":[]}}